Court Won’t Toss Suit Against Regeneron Over Alleged Fraud In Vision Drug Pricing
BOSTON — A Massachusetts federal judge on April 29 denied dismissal of a qui tam suit against Regeneron Pharmaceuticals Inc. alleging violations of the federal False Claims Act (FCA) and similar...To view the full article, register now.
Already a subscriber? Click here to view full article